Cause or effect of arteriogenesis: compositional alterations of microparticles from CAD patients undergoing external counterpulsation therapy.
about
Genome-wide identification of pathogenicity factors of the free-living amoeba Naegleria fowleri.Lipoprotein-apheresis reduces circulating microparticles in individuals with familial hypercholesterolemia.Activation of intervertebral disc cells by co-culture with notochordal cells, conditioned medium and hypoxia.Trypanosoma brucei RRM1 is a nuclear RNA-binding protein and modulator of chromatin structure.FUS/TLS contributes to replication-dependent histone gene expression by interaction with U7 snRNPs and histone-specific transcription factorsThe Aeromonas salmonicida subsp. salmonicida exoproteome: global analysis, moonlighting proteins and putative antigens for vaccination against furunculosis.The Aeromonas salmonicida subsp. salmonicida exoproteome: determination of the complete repertoire of Type-Three Secretion System effectors and identification of other virulence factors.Comprehensive proteome profiling of glioblastoma-derived extracellular vesicles identifies markers for more aggressive disease.Microparticles as potential biomarkers of cardiovascular disease.Robust Label-free, Quantitative Profiling of Circulating Plasma Microparticle (MP) Associated Proteins.The secret life of extracellular vesicles in metal homeostasis and neurodegeneration.Aberrant association of misfolded SOD1 with Na(+)/K(+)ATPase-α3 impairs its activity and contributes to motor neuron vulnerability in ALS.Marinesco-Sjögren syndrome protein SIL1 regulates motor neuron subtype-selective ER stress in ALS.Role of exosomes in hepatocellular carcinoma cell mobility alteration.Alpha-Klotho Enrichment in Induced Pluripotent Stem Cell Secretome Contributes to Antioxidative Protection in Acute Lung Injury.Applicability of extracellular vesicles in clinical studies.
P2860
Q33848854-36388043-B8A3-4CE9-A4FB-EFB23614105AQ34238659-E3149C94-537D-4102-A4B1-C2CB11D6B661Q34969332-9E38F065-5F19-4227-82C8-9F8BA03986FFQ35677560-516066B2-09FD-43EE-8327-E9DCD646989AQ35739332-19F0C85B-D756-483A-A192-2052D27441DDQ37305332-312D002F-88C5-4623-A9F4-DF9AC1D8CC26Q37367260-FCE4CA2D-E928-4736-88B6-81DFEA9D9725Q37639444-00E26050-65E4-4AA2-98D6-524ABDEB4CD4Q38334501-1C09F836-CDC6-46A6-8484-94A98051BDEBQ38386629-5361FA74-107B-4D74-B1D8-7B0D0D421B9FQ38511739-DC78C9AF-4E5C-4CCF-A0FA-E49083226093Q41087321-DDED569C-2967-4D46-83C7-DF0CC41D89C1Q42175672-9CB626A4-D554-4C59-9F91-B10446C2BF9CQ47140908-B494A160-A2A2-47E3-AB4F-42D2A83B05DBQ47309277-275737A1-4385-456C-9DF8-3BD10B458B5CQ48280242-C3DFF8D8-3B38-4311-811D-60DA93B75402
P2860
Cause or effect of arteriogenesis: compositional alterations of microparticles from CAD patients undergoing external counterpulsation therapy.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Cause or effect of arteriogene ...... rnal counterpulsation therapy.
@ast
Cause or effect of arteriogene ...... rnal counterpulsation therapy.
@en
Cause or effect of arteriogene ...... rnal counterpulsation therapy.
@nl
type
label
Cause or effect of arteriogene ...... rnal counterpulsation therapy.
@ast
Cause or effect of arteriogene ...... rnal counterpulsation therapy.
@en
Cause or effect of arteriogene ...... rnal counterpulsation therapy.
@nl
prefLabel
Cause or effect of arteriogene ...... rnal counterpulsation therapy.
@ast
Cause or effect of arteriogene ...... rnal counterpulsation therapy.
@en
Cause or effect of arteriogene ...... rnal counterpulsation therapy.
@nl
P2093
P2860
P1433
P1476
Cause or effect of arteriogene ...... rnal counterpulsation therapy.
@en
P2093
Ali Al Kaabi
Monika Stutz
Natasha Buchs
Tobias Traupe
P2860
P304
P356
10.1371/JOURNAL.PONE.0046822
P407
P577
2012-10-08T00:00:00Z